Investigational Drug Information for RPL554
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug RPL554?
RPL554 is an investigational drug.
There have been 10 clinical trials for RPL554.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 8th 2017.
The most common disease conditions in clinical trials are Lung Diseases, Pulmonary Disease, Chronic Obstructive, and Lung Diseases, Obstructive. The leading clinical trial sponsors are Verona Pharma plc, Iqvia Pty Ltd, and Cystic Fibrosis Trust.
There are thirty-one US patents protecting this investigational drug and four hundred international patents.
Summary for RPL554
| US Patents | 31 |
| International Patents | 400 |
| US Patent Applications | 108 |
| WIPO Patent Applications | 42 |
| Japanese Patent Applications | 22 |
| Clinical Trial Progress | Phase 2 (2017-02-08) |
| Vendors | 15 |
Recent Clinical Trials for RPL554
| Title | Sponsor | Phase |
|---|---|---|
| Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | IQVIA | Phase 2 |
| Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | Iqvia Pty Ltd | Phase 2 |
| Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | LGC Limited | Phase 2 |
Clinical Trial Summary for RPL554
Top disease conditions for RPL554
Top clinical trial sponsors for RPL554
US Patents for RPL554
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RPL554 | See Plans and Pricing | Inhalable pharmaceutical compositions | iCeutica Pty Ltd. (Iluka, WA, AU) | See Plans and Pricing |
| RPL554 | See Plans and Pricing | JAK inhibitors containing a 4-membered heterocyclic amide | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| RPL554 | See Plans and Pricing | Fused imidazo-piperidine JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| RPL554 | See Plans and Pricing | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | See Plans and Pricing |
| RPL554 | See Plans and Pricing | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | See Plans and Pricing |
| RPL554 | See Plans and Pricing | Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition | NITTO DENKO CORPORATION (Osaka, JP) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RPL554
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RPL554 | Australia | AU2013227351 | 2032-02-28 | See Plans and Pricing |
| RPL554 | Australia | AU2016202881 | 2032-02-28 | See Plans and Pricing |
| RPL554 | Australia | AU2017213466 | 2032-02-28 | See Plans and Pricing |
| RPL554 | Canada | CA2865702 | 2032-02-28 | See Plans and Pricing |
| RPL554 | China | CN104703584 | 2032-02-28 | See Plans and Pricing |
| RPL554 | China | CN107875127 | 2032-02-28 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
